Ticker brief
ANL
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
8
authors 14d
4
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-06-21 → 2026-06-29 · now +0.43 (−1 bearish … +1 bullish)
Who spoke4
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @bioinvestor24 | A | +1.35 | 4 | +0.52 |
| @Quantumup1 | C | -1.95 | 2 | +0.00 |
| @semodough | C | -0.75 | 1 | +0.40 |
| @Brad_E_Schulz | C | · | 1 | +0.10 |
Recent signals8of 8 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-06-29 | @Brad_E_Schulz | +0.10 | Sector performance table with percent moves and breadth counts. | · | tweet ↗ |
| 2026-06-29 | @bioinvestor24 | +0.75 | Expects ANL FOMO and says its molecule may match or beat RVMD with better preclinical profile. | · | tweet ↗ |
| 2026-06-28 | @bioinvestor24 | +0.70 | Calls ANL preclinical data compelling and more potent than RVMD, with manageable toxicity risk. | · | tweet ↗ |
| 2026-06-28 | @bioinvestor24 | +0.30 | Says AMGN obesity and oncology assets feel inadequate while peers are more competitive. | · | tweet ↗ |
| 2026-06-25 | @Quantumup1 | +0.00 | Jefferies upgraded TNGX to Buy and raised PT to $60 from $27. | · | tweet ↗ |
| 2026-06-22 | @Quantumup1 | +0.00 | RBC reiterated RVMD Outperform and $182 PT, downplays legal dispute risk. | · | tweet ↗ |
| 2026-06-22 | @semodough | +0.40 | Cantor initiated ANL at Overweight. | · | tweet ↗ |
| 2026-06-21 | @bioinvestor24 | +0.35 | Sees more upside in ERAS/ANL/TNGX than RVMD, while possible >$40B pharma deal remains. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.